ESGO 2022
Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers

Released: November 30, 2022

Expiration: November 29, 2023

Prof Isabelle Ray-Coquard
Prof Isabelle Ray-Coquard, MD, PhD
Ignace Vergote
Ignace Vergote, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:

Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer 
Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test 
Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial 
Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer